Skip to main content
SpringerLink
Log in

Comparison of PET/CT imaging with [18F]FDOPA and cholecystokinin-2 receptor targeting [68Ga]Ga-DOTA-MGS5 in a patient with advanced medullary thyroid carcinoma

  • Image of the Month
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Giovanella L, Treglia G, Iakovou I, Mihailovic J, Verburg FA, Luster M. EANM practice guideline for PET/CT imaging in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2020;47(1):61–77. https://doi.org/10.1007/s00259-019-04458-6.

    Article  PubMed  Google Scholar 

  2. Treglia G, Castaldi P, Villani MF, Perotti G, Waure C, Filice A, et al. Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2012;39(4):569–80. https://doi.org/10.1007/s00259-011-2031-6.

    Article  CAS  PubMed  Google Scholar 

  3. Reubi JC, Targeting CCK. Receptors in human cancers. Curr Top Med Chem. 2007;7(12):1239–42. https://doi.org/10.2174/156802607780960546.

    Article  CAS  PubMed  Google Scholar 

  4. Reubi JC, Waser B. Unexpected high incidence of cholecystokinin-B/gastrin receptors in human medullary thyroid carcinomas. Int J Cancer. 1996;67(5):644–7. https://doi.org/10.1002/(SICI)1097-0215(19960904)67:5<644::AID-IJC9>3.0.CO;2-U.

    Article  CAS  PubMed  Google Scholar 

  5. Klingler M, Summer D, Rangger C, Haubner R, Foster J, Sosabowski J, et al. DOTA-MGS5, a new cholecystokinin-2 receptor-targeting peptide analog with an optimized targeting profile for theranostic use. J Nucl Med. 2019;60(7):1010–6. https://doi.org/10.2967/jnumed.118.221283.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Author notes

  1. Christian Uprimny and Elisabeth von Guggenberg contributed equally to this work.

Authors and Affiliations

  1. Department of Nuclear Medicine, Medical University Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria

    Christian Uprimny, Elisabeth von Guggenberg, Anna Svirydenka & Irene Johanna Virgolini

  2. Radioisotope Centre POLATOM, National Centre for Nuclear Research, Otwock, Poland

    Renata Mikołajczak

  3. Department of Endocrinology, Jagiellonian University Medical College, Krakow, Poland

    Alicja Hubalewska-Dydejczyk

Authors
  1. Christian Uprimny
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elisabeth von Guggenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anna Svirydenka
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Renata Mikołajczak
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alicja Hubalewska-Dydejczyk
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Irene Johanna Virgolini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christian Uprimny.

Ethics declarations

All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee. Written informed consent was given by the patient prior to the exams together with the permission for anonymised publication of the related medical data. [68Ga]Ga-DOTA-MGS5 was used on a named patient basis and prepared according to the Austrian Medicinal Products Act (AMG §8 and §62).

Conflict of interest

The Medical University of Innsbruck has filed a patent application for minigastrin analogues with “Improved pharmacokinetics and cholecystokinin-2 receptor (CCK2R) targeting for diagnosis and therapy”. All other authors have nothing to disclose.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Image of the month

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Uprimny, C., von Guggenberg, E., Svirydenka, A. et al. Comparison of PET/CT imaging with [18F]FDOPA and cholecystokinin-2 receptor targeting [68Ga]Ga-DOTA-MGS5 in a patient with advanced medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 48, 935–936 (2021). https://doi.org/10.1007/s00259-020-04963-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-020-04963-z

Search

Navigation